Multimodal data infrastructure
The platform combines wet lab, computational, and proxy biological data so AI models can be trained on multiple evidence types rather than a single dataset.
1910
Подтвердить1910 is an AI-native biotech company offering the ITO™ platform for multimodal drug discovery. It helps pharma partners combine wet lab, computational, and proxy data to design therapeutics.
What 1910 is
1910 is an AI-native biotech company built around its ITO™ platform, which it describes as a multimodal, modality-agnostic infrastructure for pharma. The platform is designed to integrate wet lab, computational, and proxy data with frontier AI models and high-throughput lab automation.
The company says the system is intended to help teams design, test, and develop small and large molecule therapeutics with a more iterative workflow. Public pages emphasize data orchestration, model training, federated learning, and robotics-driven validation as the main pieces of that workflow, along with partnering models for companies that want to embed or collaborate on the platform.
Core capabilities
Data preparation and curation
Its Data Orchestration step formats, analyzes, cleans, annotates, curates, and featurizes data before model ingestion.
Model Foundry™
The Model Foundry™ is described as a collection of hundreds of AI/ML models plus a multi-AI agent system for drug discovery optimization.
Federated learning workflow
Federated learning is used in pre-competitive consortium settings so partners can train on blinded datasets without moving private data out of their own environments.
Lab-in-the-loop validation
The platform includes robotics-driven lab validation and high-throughput assay generation to feed experimental results back into the design loop.
Partner delivery options
Partnering materials describe outputs and modules for small molecules, large molecules, data packages, and interactive tools such as dashboards and chatbots.
Where it fits
End-to-end drug discovery
Teams building early-stage therapeutics can use the platform to combine multimodal data, model generation, and lab validation in one loop for small or large molecule programs.
Collaborative model training
Consortia or partner networks can use federated learning to fine-tune shared AI models without transferring private datasets between organizations.
Internal platform deployment
Organizations with existing R&D teams can embed the ITO™ platform internally and customize it to address their own discovery bottlenecks.
Data and asset licensing
Partners seeking a narrower commercial arrangement can license lead compounds or license disease-relevant multimodal data for model building and target identification.
Pros and Cons
Pros
- Combines multiple data types, including wet lab, computational, and proxy biological data.
- Provides a structured workflow from data orchestration through modeling and lab validation.
- Supports both small molecule and large molecule discovery use cases.
- Offers federated learning for collaborative work where private data stays local.
- Includes multiple partnering models, from co-engineering to licensing.
Cons
- The site does not publish pricing, and the pricing URL currently resolves to a not found page.
- Public pages give a strong platform overview, but they provide limited detail on concrete integrations, implementation requirements, or customer-specific setup.
FAQ
What does 1910 provide?
1910 positions its ITO™ platform as an AI infrastructure for pharma that combines multimodal data, frontier AI models, and laboratory automation to support drug discovery and development. The platform is described as modality-agnostic and intended for small and large molecule programs.
What kinds of capabilities are included in the platform?
The site describes the platform as integrating wet lab, computational, and proxy biological data. It also mentions features such as multimodal data orchestration, a Model Foundry™, federated learning, and robotics-driven wet lab validation.
How can companies work with 1910?
1910 presents partnering options for embedding the platform inside an organization, co-engineering discovery modules, co-discovery of therapeutic candidates, platform-as-a-service access in development, asset licensing, and data licensing.
Where does the platform run?
The platform page says the system is cloud-based on Microsoft Azure and notes that it can be replicated on other major cloud providers including AWS, Google Cloud, Oracle Cloud, and more.
Is pricing published?
No public pricing is shown on the site. The pricing URL currently returns a not found page, so commercial terms appear to be handled through partnering or direct inquiry rather than a published price list.
Quick Facts
- Category
- AI-native biotech platform
- Primary users
- Pharma, biotech, VCs and lab incubators, academia, and government partners
- Platform name
- ITO™
- Source domain
- 1910genetics.com
- Pricing
- Not publicly listed
- Deployment
- Cloud-based; built on Microsoft Azure